Dementia affects many people worldwide, and scientists are still looking for ways to cure it, which entails first finding ...

Tools created in Mayo Clinic's Neurobiology of Parkinson's Disease and Related Disorders aid rapid screening of compound libraries for chemicals targeting oligomeric stage of fibrillization.

Mayo Clinic's Neurobiology of Parkinson's Disease and Related Disorders Lab showed that small aggregates of alpha-synuclein ...

Although our cellular clocks differ dramatically, scientists argue that human aging is one of the highest risk factors for a ...

Ambio will test ibogaine, an experimental, naturally occurring psychedelic, as a therapy for neurodegenerative conditions ...

A new clinical trial to treat Parkinson’s disease will start in Perth next year using a drug currently being tested as a ...

Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient's own T cells, which ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

The FDA has accepted for review the resubmitted NDA for ND0612 for the treatment of motor fluctuations in patients with Parkinson disease.

Some doctors told him he'd live with the disease forever, but Khaled Alsheebani never stopped believing treatments would advance one day.

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second ...

The FDA has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat Parkinson’s ...